
    
      Primary Effectiveness Endpoint: A clinically significant reduction in GERD symptoms,
      specifically "Troublesome" regurgitation with or without heartburn assessed by the Reflux
      Disease Questionnaire (RDQ).

      Troublesome symptoms are those which occur a minimum of 2 days a week and are at least
      moderate in severity.

      Secondary Effectiveness Endpoint: The normalization of esophageal acid exposure at 6 months
      and a clinically significant reduction in PPI usage at 12 months.
    
  